{ "data": { "id": "org_state-council-of-china", "slug": "state-council-of-china", "name": "State Council of China", "short_name": "State Council", "type": "government", "tier": 1, "homepage": "https://www.gov.cn", "country_code": "CN", "reliability_note": null, "url": "https://statorigin.org/sources/state-council-of-china", "documents": [ { "title": "Value of China's innovative drug out-licensing deals hit new high in H1", "url": "https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 7 }, { "title": "China scales up support for clinical trials, accelerating drug development", "url": "https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 3 }, { "title": "China updates national medical insurance catalog, adds 114 new drugs", "url": "https://english.www.gov.cn/news/202512/07/content_WS6934f5f6c6d00ca5f9a07f64.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 4 }, { "title": "全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网", "url": "https://www.gov.cn/zhengce/202501/content_6997982.htm", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 2 }, { "title": "Measures facilitate approval of 48 first-in-class innovative drugs", "url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 12 }, { "title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 10 }, { "title": "China to expand health insurance coverage for innovative drugs", "url": "https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 6 } ], "statistics": [ { "id": "stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4", "url": "https://statorigin.org/stat/stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4", "indicator": { "slug": "approved-innovative-drugs-designated-as-breakthrough-therapies", "name": "Approved innovative drugs designated as breakthrough therapies", "definition": "Number of approved innovative drugs that previously received breakthrough therapy designation during development." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 13, "value_text": "13", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4", "bibtex": "@misc{statecouncil2024approvedqdwka4,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_R7VPZ3Y198V455WDHSD3E3W11N", "url": "https://statorigin.org/stat/stat_R7VPZ3Y198V455WDHSD3E3W11N", "indicator": { "slug": "beneficiaries-of-negotiated-reimbursement-drugs", "name": "Beneficiaries of negotiated reimbursement drugs", "definition": "Cumulative count of patient visits or individuals benefiting from price-negotiated reimbursement medicines." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 830, "value_text": "8.3亿人次", "unit": "count", "currency": null, "scale": "million", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "7年累计将835种药品新增进入目录", "quote": "截至2024年10月底，医保基金为协议期内谈判药品支付累计超过3500亿元，惠及患者8.3亿人次。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_R7VPZ3Y198V455WDHSD3E3W11N", "bibtex": "@misc{statecouncil2024beneficiariese3w11n,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_R7VPZ3Y198V455WDHSD3E3W11N},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_KJM61RPXMKJJR9W1K7556F9HW5", "url": "https://statorigin.org/stat/stat_KJM61RPXMKJJR9W1K7556F9HW5", "indicator": { "slug": "clinical-trial-registrations", "name": "Clinical trial registrations", "definition": "Number of clinical trials registered on the International Clinical Trials Registry Platform." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 3358, "value_text": "3,358", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China scales up support for clinical trials, accelerating drug development", "document_url": "https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html", "document_type": "press_release", "locator": "China scales up support for clinical trials, accelerating drug development", "quote": "A total of 3,358 clinical trials of drugs were registered in China in 2021, 3,410 in 2022, and 4,300 in 2023, indicating continuous growth, according to an industry report.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2021). China scales up support for clinical trials, accelerating drug development. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html. Via StatOrigin, https://statorigin.org/stat/stat_KJM61RPXMKJJR9W1K7556F9HW5", "bibtex": "@misc{statecouncil2021clinical6f9hw5,\n author = {{State Council of China}},\n title = {China scales up support for clinical trials, accelerating drug development},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KJM61RPXMKJJR9W1K7556F9HW5},\n note = {Original source: https://english.www.gov.cn/news/202405/21/content\\_WS664be047c6d0868f4e8e74ae.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_3E4RA23KG2414RKK4KT0JHAKQ4", "url": "https://statorigin.org/stat/stat_3E4RA23KG2414RKK4KT0JHAKQ4", "indicator": { "slug": "clinical-trial-registrations", "name": "Clinical trial registrations", "definition": "Number of clinical trials registered on the International Clinical Trials Registry Platform." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 3410, "value_text": "3,410", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China scales up support for clinical trials, accelerating drug development", "document_url": "https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html", "document_type": "press_release", "locator": "China scales up support for clinical trials, accelerating drug development", "quote": "A total of 3,358 clinical trials of drugs were registered in China in 2021, 3,410 in 2022, and 4,300 in 2023, indicating continuous growth, according to an industry report.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2022). China scales up support for clinical trials, accelerating drug development. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html. Via StatOrigin, https://statorigin.org/stat/stat_3E4RA23KG2414RKK4KT0JHAKQ4", "bibtex": "@misc{statecouncil2022clinicaljhakq4,\n author = {{State Council of China}},\n title = {China scales up support for clinical trials, accelerating drug development},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_3E4RA23KG2414RKK4KT0JHAKQ4},\n note = {Original source: https://english.www.gov.cn/news/202405/21/content\\_WS664be047c6d0868f4e8e74ae.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_BPHX2XQA3EV4G1QEV7GMRP4BQW", "url": "https://statorigin.org/stat/stat_BPHX2XQA3EV4G1QEV7GMRP4BQW", "indicator": { "slug": "clinical-trial-registrations", "name": "Clinical trial registrations", "definition": "Number of clinical trials registered on the International Clinical Trials Registry Platform." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 4300, "value_text": "4,300", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China scales up support for clinical trials, accelerating drug development", "document_url": "https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html", "document_type": "press_release", "locator": "China scales up support for clinical trials, accelerating drug development", "quote": "A total of 3,358 clinical trials of drugs were registered in China in 2021, 3,410 in 2022, and 4,300 in 2023, indicating continuous growth, according to an industry report.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2023). China scales up support for clinical trials, accelerating drug development. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html. Via StatOrigin, https://statorigin.org/stat/stat_BPHX2XQA3EV4G1QEV7GMRP4BQW", "bibtex": "@misc{statecouncil2023clinicalrp4bqw,\n author = {{State Council of China}},\n title = {China scales up support for clinical trials, accelerating drug development},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_BPHX2XQA3EV4G1QEV7GMRP4BQW},\n note = {Original source: https://english.www.gov.cn/news/202405/21/content\\_WS664be047c6d0868f4e8e74ae.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX", "url": "https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX", "indicator": { "slug": "cumulative-drug-approval-applications-under-priority-review", "name": "Cumulative drug approval applications under priority review", "definition": "Total cumulative number of drug approval applications granted priority review status since program inception." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "point" }, "value": 496, "value_text": "496", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX", "bibtex": "@misc{statecouncil2024cumulative0hd2xx,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_640MTW4RSR1CFHGBHRK9NV0ZST", "url": "https://statorigin.org/stat/stat_640MTW4RSR1CFHGBHRK9NV0ZST", "indicator": { "slug": "cumulative-health-insurance-fund-payout-for-negotiated-medicines", "name": "Cumulative health insurance fund payout for negotiated medicines", "definition": "Cumulative expenditures paid by the basic medical insurance fund for medicines under negotiation agreements." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 350, "value_text": "超过3500亿元", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "7年累计将835种药品新增进入目录", "quote": "截至2024年10月底，医保基金为协议期内谈判药品支付累计超过3500亿元，惠及患者8.3亿人次。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_640MTW4RSR1CFHGBHRK9NV0ZST", "bibtex": "@misc{statecouncil2024cumulativenv0zst,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_640MTW4RSR1CFHGBHRK9NV0ZST},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_W4J65YEFH7G94MC1DDV7JPRX95", "url": "https://statorigin.org/stat/stat_W4J65YEFH7G94MC1DDV7JPRX95", "indicator": { "slug": "cumulative-negotiated-drug-sales-during-agreement-period", "name": "Cumulative negotiated drug sales during agreement period", "definition": "Total sales revenue generated by newly negotiated medicines during their agreement period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 510, "value_text": "超5100亿元", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "7年累计将835种药品新增进入目录", "quote": "截至2024年10月底，医保谈判新增药品协议期内销售超5100亿元，医保基金支出超3500亿元，如此大规模的资金主要是在原有支出结构中进行优化调整，没有大幅增加群众缴费负担。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_W4J65YEFH7G94MC1DDV7JPRX95", "bibtex": "@misc{statecouncil2024cumulativejprx95,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_W4J65YEFH7G94MC1DDV7JPRX95},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_YSAHE1MWZAG4P4M02KP1K163HE", "url": "https://statorigin.org/stat/stat_YSAHE1MWZAG4P4M02KP1K163HE", "indicator": { "slug": "domestic-innovative-drug-approvals-half-year", "name": "Domestic innovative drug approvals (half year)", "definition": "Total number of domestically developed innovative drugs approved for marketing within a specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 31, "value_text": "31", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Value of China's innovative drug out-licensing deals hit new high in H1", "document_url": "https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html", "document_type": "press_release", "locator": "Value of China's innovative drug out-licensing deals hit new high in H1", "quote": "China approved 38 innovative drugs for marketing during the period, including 31 developed by domestic companies, Tao Qing, head of the bureau for operation, monitoring and coordination with the MIIT, told a media conference.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). Value of China's innovative drug out-licensing deals hit new high in H1. Retrieved September 17, 2026, from https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Via StatOrigin, https://statorigin.org/stat/stat_YSAHE1MWZAG4P4M02KP1K163HE", "bibtex": "@misc{statecouncil2026domestick163he,\n author = {{State Council of China}},\n title = {Value of China's innovative drug out-licensing deals hit new high in H1},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_YSAHE1MWZAG4P4M02KP1K163HE},\n note = {Original source: https://english.www.gov.cn/archive/statistics/202607/20/content\\_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_H5F73ZBGZ25X2CHM3KGD612188", "url": "https://statorigin.org/stat/stat_H5F73ZBGZ25X2CHM3KGD612188", "indicator": { "slug": "drug-approval-applications-completed-under-priority-review", "name": "Drug approval applications completed under priority review", "definition": "Total number of drug approval applications completed under an expedited priority review pathway." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 110, "value_text": "110", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "\"In 2024, the administration completed 110 drug approval applications covering 74 different categories under the priority review pathway, marking a year-on-year increase of 29 percent,\" Yuan said.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_H5F73ZBGZ25X2CHM3KGD612188", "bibtex": "@misc{statecouncil2024drug612188,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_H5F73ZBGZ25X2CHM3KGD612188},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_2NX1KV5HC4NMCVAHKYZ4MV25FZ", "url": "https://statorigin.org/stat/stat_2NX1KV5HC4NMCVAHKYZ4MV25FZ", "indicator": { "slug": "drugs-in-commercial-health-insurance-innovative-drug-catalog", "name": "Drugs in commercial health insurance innovative drug catalog", "definition": "Total number of innovative drugs included in the commercial health insurance innovative drug catalog." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-12-07", "end": "2025-12-07", "type": "point" }, "value": 19, "value_text": "19", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China updates national medical insurance catalog, adds 114 new drugs", "document_url": "https://english.www.gov.cn/news/202512/07/content_WS6934f5f6c6d00ca5f9a07f64.html", "document_type": "press_release", "locator": "China updates national medical insurance catalog, adds 114 new drugs", "quote": "The commercial insurance innovative drug list included 19 drugs for the treatment of tumors, rare diseases, and Alzheimer's, among others.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2025). China updates national medical insurance catalog, adds 114 new drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202512/07/content_WS6934f5f6c6d00ca5f9a07f64.html. Via StatOrigin, https://statorigin.org/stat/stat_2NX1KV5HC4NMCVAHKYZ4MV25FZ", "bibtex": "@misc{statecouncil2025drugsmv25fz,\n author = {{State Council of China}},\n title = {China updates national medical insurance catalog, adds 114 new drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_2NX1KV5HC4NMCVAHKYZ4MV25FZ},\n note = {Original source: https://english.www.gov.cn/news/202512/07/content\\_WS6934f5f6c6d00ca5f9a07f64.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_9N4VH7NEJBTHP6G9SAQAE1RFJ7", "url": "https://statorigin.org/stat/stat_9N4VH7NEJBTHP6G9SAQAE1RFJ7", "indicator": { "slug": "drugs-removed-from-national-reimbursement-drug-list", "name": "Drugs removed from national reimbursement drug list", "definition": "Count of drugs excluded or delisted from a national reimbursement drug list during a catalog adjustment cycle." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 43, "value_text": "43种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药", "quote": "91种药品中，有89种以谈判/竞价方式纳入，2种国家集采中选药品直接纳入，同时43种临床已被替代或长期未生产供应的药品被调出。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_9N4VH7NEJBTHP6G9SAQAE1RFJ7", "bibtex": "@misc{statecouncil2024drugse1rfj7,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_9N4VH7NEJBTHP6G9SAQAE1RFJ7},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_7ZQGJBK4NK0Z4W8E5R0X0WMRCK", "url": "https://statorigin.org/stat/stat_7ZQGJBK4NK0Z4W8E5R0X0WMRCK", "indicator": { "slug": "first-in-class-drug-approvals", "name": "First-in-class drug approvals", "definition": "Number of approved therapeutic drugs featuring a novel biological mechanism of action." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 48, "value_text": "48", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare diseases, thanks to measures aimed at enhancing review efficiency and accelerating patient access to novel therapies, according to a report released on Tuesday by the National Medical Products Administration.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_7ZQGJBK4NK0Z4W8E5R0X0WMRCK", "bibtex": "@misc{statecouncil2024first0wmrck,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7ZQGJBK4NK0Z4W8E5R0X0WMRCK},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_B0F5N0J09FDXKE4QQEMHMA6VZD", "url": "https://statorigin.org/stat/stat_B0F5N0J09FDXKE4QQEMHMA6VZD", "indicator": { "slug": "first-in-class-drug-approvals", "name": "First-in-class drug approvals", "definition": "Number of approved therapeutic drugs featuring a novel biological mechanism of action." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 40, "value_text": "40", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "The number was the highest in the past five years, compared with 40 in 2023 and 21 in 2022.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2023). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_B0F5N0J09FDXKE4QQEMHMA6VZD", "bibtex": "@misc{statecouncil2023firstma6vzd,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_B0F5N0J09FDXKE4QQEMHMA6VZD},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_E3DENM4QEGBXFVT0TMPS0FQQNS", "url": "https://statorigin.org/stat/stat_E3DENM4QEGBXFVT0TMPS0FQQNS", "indicator": { "slug": "first-in-class-drug-approvals", "name": "First-in-class drug approvals", "definition": "Number of approved therapeutic drugs featuring a novel biological mechanism of action." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 21, "value_text": "21", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "The number was the highest in the past five years, compared with 40 in 2023 and 21 in 2022.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2022). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_E3DENM4QEGBXFVT0TMPS0FQQNS", "bibtex": "@misc{statecouncil2022first0fqqns,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_E3DENM4QEGBXFVT0TMPS0FQQNS},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_A8YRMP6Q59EECC6PK533H1FWWA", "url": "https://statorigin.org/stat/stat_A8YRMP6Q59EECC6PK533H1FWWA", "indicator": { "slug": "globally-new-innovative-drugs-added-to-reimbursement-drug-list", "name": "Globally new innovative drugs added to reimbursement drug list", "definition": "Number of first-in-class or globally new innovative medicines newly included in the reimbursement drug list." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 38, "value_text": "38种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "“全球新”的创新药有38种，创历年新高", "quote": "新增91种药品中，38种是“全球新”的创新药，无论是比例还是绝对数量都创历年新高。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_A8YRMP6Q59EECC6PK533H1FWWA", "bibtex": "@misc{statecouncil2024globallyh1fwwa,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_A8YRMP6Q59EECC6PK533H1FWWA},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_C8F9C5Q0MY85N20BPY0TA0T7SQ", "url": "https://statorigin.org/stat/stat_C8F9C5Q0MY85N20BPY0TA0T7SQ", "indicator": { "slug": "innovative-drug-approvals", "name": "Innovative drug approvals", "definition": "Total number of innovative pharmaceutical products granted regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 48, "value_text": "48个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202501/content_6997982.htm", "document_type": "press_release", "locator": "大力支持产业创新", "quote": "国家药监局统计显示，2024年累计批准上市创新药48个、创新医疗器械65个。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202501/content_6997982.htm. Via StatOrigin, https://statorigin.org/stat/stat_C8F9C5Q0MY85N20BPY0TA0T7SQ", "bibtex": "@misc{statecouncil2024innovativea0t7sq,\n author = {{State Council of China}},\n title = {全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_C8F9C5Q0MY85N20BPY0TA0T7SQ},\n note = {Original source: https://www.gov.cn/zhengce/202501/content\\_6997982.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_WZQGKCJ44HNCBQ89JGQ0HBW2D2", "url": "https://statorigin.org/stat/stat_WZQGKCJ44HNCBQ89JGQ0HBW2D2", "indicator": { "slug": "innovative-drug-approvals-half-year", "name": "Innovative drug approvals (half year)", "definition": "Total number of innovative pharmaceutical products granted regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 38, "value_text": "38", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Value of China's innovative drug out-licensing deals hit new high in H1", "document_url": "https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html", "document_type": "press_release", "locator": "Value of China's innovative drug out-licensing deals hit new high in H1", "quote": "China approved 38 innovative drugs for marketing during the period, including 31 developed by domestic companies, Tao Qing, head of the bureau for operation, monitoring and coordination with the MIIT, told a media conference.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). Value of China's innovative drug out-licensing deals hit new high in H1. Retrieved September 17, 2026, from https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Via StatOrigin, https://statorigin.org/stat/stat_WZQGKCJ44HNCBQ89JGQ0HBW2D2", "bibtex": "@misc{statecouncil2026innovativehbw2d2,\n author = {{State Council of China}},\n title = {Value of China's innovative drug out-licensing deals hit new high in H1},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_WZQGKCJ44HNCBQ89JGQ0HBW2D2},\n note = {Original source: https://english.www.gov.cn/archive/statistics/202607/20/content\\_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_7DSPGYME3SEXR5ZB9KQSHVYE51", "url": "https://statorigin.org/stat/stat_7DSPGYME3SEXR5ZB9KQSHVYE51", "indicator": { "slug": "innovative-drug-negotiation-success-rate", "name": "Innovative drug negotiation success rate", "definition": "Percentage of innovative drugs successfully negotiated for inclusion in the reimbursement drug list." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 90, "value_text": "90%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "“全球新”的创新药有38种，创历年新高", "quote": "在谈判阶段，创新药的谈判成功率超过90%，较总体成功率高16个百分点。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_7DSPGYME3SEXR5ZB9KQSHVYE51", "bibtex": "@misc{statecouncil2024innovativehvye51,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7DSPGYME3SEXR5ZB9KQSHVYE51},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_M4C4PFSZGMYXXQMTX08MF8QXZ5", "url": "https://statorigin.org/stat/stat_M4C4PFSZGMYXXQMTX08MF8QXZ5", "indicator": { "slug": "innovative-drug-out-licensing-deal-value-half-year", "name": "Innovative drug out-licensing deal value (half year)", "definition": "Total monetary value of out-licensing agreements signed for innovative pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 100, "value_text": "100 billion U.S. dollars", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Value of China's innovative drug out-licensing deals hit new high in H1", "document_url": "https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html", "document_type": "press_release", "locator": "Value of China's innovative drug out-licensing deals hit new high in H1", "quote": "The total value of China's innovative drug out-licensing deals exceeded 100 billion U.S. dollars in the first half of the year, reaching a record high, the Ministry of Industry and Information Technology (MIIT) said Monday.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). Value of China's innovative drug out-licensing deals hit new high in H1. Retrieved September 17, 2026, from https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Via StatOrigin, https://statorigin.org/stat/stat_M4C4PFSZGMYXXQMTX08MF8QXZ5", "bibtex": "@misc{statecouncil2026innovativef8qxz5,\n author = {{State Council of China}},\n title = {Value of China's innovative drug out-licensing deals hit new high in H1},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_M4C4PFSZGMYXXQMTX08MF8QXZ5},\n note = {Original source: https://english.www.gov.cn/archive/statistics/202607/20/content\\_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_PZ26BJ8VTRJ1VBH8PDXM6YTAHF", "url": "https://statorigin.org/stat/stat_PZ26BJ8VTRJ1VBH8PDXM6YTAHF", "indicator": { "slug": "innovative-drug-out-licensing-deal-value-half-year", "name": "Innovative drug out-licensing deal value (half year)", "definition": "Total monetary value of out-licensing agreements signed for innovative pharmaceutical products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 100, "value_text": "more than 100 billion U.S. dollars", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China to expand health insurance coverage for innovative drugs", "document_url": "https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html", "document_type": "press_release", "locator": "China to expand health insurance coverage for innovative drugs", "quote": "In the first half of 2026, the total value of China's innovative drug out-licensing deals reached a record high of more than 100 billion U.S. dollars, according to the Ministry of Industry and Information Technology.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). China to expand health insurance coverage for innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html. Via StatOrigin, https://statorigin.org/stat/stat_PZ26BJ8VTRJ1VBH8PDXM6YTAHF", "bibtex": "@misc{statecouncil2026innovative6ytahf,\n author = {{State Council of China}},\n title = {China to expand health insurance coverage for innovative drugs},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PZ26BJ8VTRJ1VBH8PDXM6YTAHF},\n note = {Original source: https://english.www.gov.cn/news/202609/04/content\\_WS6a9a7481c6d00ca5f9a0d02f.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_26V7DYYJWWWK6M0WSR8VQM5ZP9", "url": "https://statorigin.org/stat/stat_26V7DYYJWWWK6M0WSR8VQM5ZP9", "indicator": { "slug": "innovative-drugs-added-to-national-health-insurance-catalog", "name": "Innovative drugs added to national health insurance catalog", "definition": "Number of innovative drugs newly added to the national health insurance drug catalog." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-12-07", "end": "2025-12-07", "type": "point" }, "value": 50, "value_text": "50", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China updates national medical insurance catalog, adds 114 new drugs", "document_url": "https://english.www.gov.cn/news/202512/07/content_WS6934f5f6c6d00ca5f9a07f64.html", "document_type": "press_release", "locator": "China updates national medical insurance catalog, adds 114 new drugs", "quote": "The updated national medical insurance drug list has added 114 drugs, among which 50 are innovative pharmaceuticals.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2025). China updates national medical insurance catalog, adds 114 new drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202512/07/content_WS6934f5f6c6d00ca5f9a07f64.html. Via StatOrigin, https://statorigin.org/stat/stat_26V7DYYJWWWK6M0WSR8VQM5ZP9", "bibtex": "@misc{statecouncil2025innovativeqm5zp9,\n author = {{State Council of China}},\n title = {China updates national medical insurance catalog, adds 114 new drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_26V7DYYJWWWK6M0WSR8VQM5ZP9},\n note = {Original source: https://english.www.gov.cn/news/202512/07/content\\_WS6934f5f6c6d00ca5f9a07f64.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1NVCEW462ZMZA6AJ9Z49RXRYV0", "url": "https://statorigin.org/stat/stat_1NVCEW462ZMZA6AJ9Z49RXRYV0", "indicator": { "slug": "innovative-drugs-added-to-national-health-insurance-drug-list", "name": "Innovative drugs added to national health insurance drug list", "definition": "Cumulative number of innovative drugs added to the national health insurance reimbursement drug list over a given period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2026-09-04", "type": "point" }, "value": 199, "value_text": "199", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China to expand health insurance coverage for innovative drugs", "document_url": "https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html", "document_type": "press_release", "locator": "China to expand health insurance coverage for innovative drugs", "quote": "Since 2018, China has added 949 medicines to its national health insurance drug list, including 199 innovative drugs, Li Tao, deputy head of the National Healthcare Security Administration, said at a news conference on Friday.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). China to expand health insurance coverage for innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html. Via StatOrigin, https://statorigin.org/stat/stat_1NVCEW462ZMZA6AJ9Z49RXRYV0", "bibtex": "@misc{statecouncil2026innovativerxryv0,\n author = {{State Council of China}},\n title = {China to expand health insurance coverage for innovative drugs},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1NVCEW462ZMZA6AJ9Z49RXRYV0},\n note = {Original source: https://english.www.gov.cn/news/202609/04/content\\_WS6a9a7481c6d00ca5f9a0d02f.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_9E0TKNHD7PSBZ4Y6MVG57MSZP3", "url": "https://statorigin.org/stat/stat_9E0TKNHD7PSBZ4Y6MVG57MSZP3", "indicator": { "slug": "innovative-drugs-approved-via-priority-review-pathway", "name": "Innovative drugs approved via priority review pathway", "definition": "Number of innovative drugs approved for marketing through expedited priority review procedures." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 17, "value_text": "17", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_9E0TKNHD7PSBZ4Y6MVG57MSZP3", "bibtex": "@misc{statecouncil2024innovative7mszp3,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_9E0TKNHD7PSBZ4Y6MVG57MSZP3},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_QAS5BVRKBGACJPJMJMVC2BP2B0", "url": "https://statorigin.org/stat/stat_QAS5BVRKBGACJPJMJMVC2BP2B0", "indicator": { "slug": "innovative-drugs-granted-conditional-market-approval", "name": "Innovative drugs granted conditional market approval", "definition": "Number of innovative pharmaceuticals granted conditional marketing authorization based on surrogate or preliminary clinical endpoints." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 11, "value_text": "11", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_QAS5BVRKBGACJPJMJMVC2BP2B0", "bibtex": "@misc{statecouncil2024innovative2bp2b0,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QAS5BVRKBGACJPJMJMVC2BP2B0},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_T6E8YF7MT69ZWNA9WXQ62WCA15", "url": "https://statorigin.org/stat/stat_T6E8YF7MT69ZWNA9WXQ62WCA15", "indicator": { "slug": "medicines-added-to-national-health-insurance-drug-list", "name": "Medicines added to national health insurance drug list", "definition": "Cumulative number of medicines added to the national health insurance reimbursement drug list over a given period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2026-09-04", "type": "point" }, "value": 949, "value_text": "949", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China to expand health insurance coverage for innovative drugs", "document_url": "https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html", "document_type": "press_release", "locator": "China to expand health insurance coverage for innovative drugs", "quote": "Since 2018, China has added 949 medicines to its national health insurance drug list, including 199 innovative drugs, Li Tao, deputy head of the National Healthcare Security Administration, said at a news conference on Friday.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). China to expand health insurance coverage for innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html. Via StatOrigin, https://statorigin.org/stat/stat_T6E8YF7MT69ZWNA9WXQ62WCA15", "bibtex": "@misc{statecouncil2026medicines2wca15,\n author = {{State Council of China}},\n title = {China to expand health insurance coverage for innovative drugs},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_T6E8YF7MT69ZWNA9WXQ62WCA15},\n note = {Original source: https://english.www.gov.cn/news/202609/04/content\\_WS6a9a7481c6d00ca5f9a0d02f.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_68RECPWHZ2YX4EB52HV41K9S5T", "url": "https://statorigin.org/stat/stat_68RECPWHZ2YX4EB52HV41K9S5T", "indicator": { "slug": "negotiated-or-bid-drugs-added-to-national-reimbursement-drug-list-annual", "name": "Negotiated or bid drugs added to national reimbursement drug list (annual)", "definition": "Number of drugs admitted to a national reimbursement drug list through price negotiations or competitive bidding." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 89, "value_text": "89种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药", "quote": "91种药品中，有89种以谈判/竞价方式纳入，2种国家集采中选药品直接纳入，同时43种临床已被替代或长期未生产供应的药品被调出。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_68RECPWHZ2YX4EB52HV41K9S5T", "bibtex": "@misc{statecouncil2024negotiated1k9s5t,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_68RECPWHZ2YX4EB52HV41K9S5T},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HRDWBEV2399JQDV7NVM8B650DC", "url": "https://statorigin.org/stat/stat_HRDWBEV2399JQDV7NVM8B650DC", "indicator": { "slug": "newly-added-drugs-in-national-reimbursement-drug-list", "name": "Newly added drugs in national reimbursement drug list", "definition": "Total count of new drug varieties incorporated into a national reimbursement drug list during a catalog adjustment cycle." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-12-07", "end": "2025-12-07", "type": "point" }, "value": 114, "value_text": "114", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China updates national medical insurance catalog, adds 114 new drugs", "document_url": "https://english.www.gov.cn/news/202512/07/content_WS6934f5f6c6d00ca5f9a07f64.html", "document_type": "press_release", "locator": "China updates national medical insurance catalog, adds 114 new drugs", "quote": "The updated national medical insurance drug list has added 114 drugs, among which 50 are innovative pharmaceuticals.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2025). China updates national medical insurance catalog, adds 114 new drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202512/07/content_WS6934f5f6c6d00ca5f9a07f64.html. Via StatOrigin, https://statorigin.org/stat/stat_HRDWBEV2399JQDV7NVM8B650DC", "bibtex": "@misc{statecouncil2025newlyb650dc,\n author = {{State Council of China}},\n title = {China updates national medical insurance catalog, adds 114 new drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HRDWBEV2399JQDV7NVM8B650DC},\n note = {Original source: https://english.www.gov.cn/news/202512/07/content\\_WS6934f5f6c6d00ca5f9a07f64.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_KHPW7R2JV7YGJR5EZBRG3TJ1NA", "url": "https://statorigin.org/stat/stat_KHPW7R2JV7YGJR5EZBRG3TJ1NA", "indicator": { "slug": "newly-added-drugs-in-national-reimbursement-drug-list-annual", "name": "Newly added drugs in national reimbursement drug list (annual)", "definition": "Total count of new drug varieties incorporated into a national reimbursement drug list during a catalog adjustment cycle." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 91, "value_text": "91种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药", "quote": "在今年的调整中，有91种药品新增进入国家医保药品目录，药品总数增至3159种，目录自2025年1月1日起实施。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_KHPW7R2JV7YGJR5EZBRG3TJ1NA", "bibtex": "@misc{statecouncil2024newly3tj1na,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KHPW7R2JV7YGJR5EZBRG3TJ1NA},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_ATWKB693AP7BKEMW05WVGC6VK5", "url": "https://statorigin.org/stat/stat_ATWKB693AP7BKEMW05WVGC6VK5", "indicator": { "slug": "pediatric-medicine-approvals", "name": "Pediatric medicine approvals", "definition": "Number of pediatric medicines granted market approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 106, "value_text": "106", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "In addition, China approved 106 pediatric medicines, and 35 medications were granted expanded pediatric indications, which is expected to help alleviate the shortage of pediatric medication options, the report said.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_ATWKB693AP7BKEMW05WVGC6VK5", "bibtex": "@misc{statecouncil2024pediatricgc6vk5,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_ATWKB693AP7BKEMW05WVGC6VK5},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_V4A11XKC36RNQHBB08S64ACRHN", "url": "https://statorigin.org/stat/stat_V4A11XKC36RNQHBB08S64ACRHN", "indicator": { "slug": "pharmaceutical-export-delivery-value-growth-half-year", "name": "Pharmaceutical export delivery value growth (half year)", "definition": "Year-on-year growth rate of pharmaceutical industry export delivery value." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 9, "value_text": "9 percent", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Value of China's innovative drug out-licensing deals hit new high in H1", "document_url": "https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html", "document_type": "press_release", "locator": "Value of China's innovative drug out-licensing deals hit new high in H1", "quote": "The industry's export delivery value exceeded 210 billion yuan (about 30.91 billion U.S. dollars) in the first six months, up 9 percent from a year earlier.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). Value of China's innovative drug out-licensing deals hit new high in H1. Retrieved September 17, 2026, from https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Via StatOrigin, https://statorigin.org/stat/stat_V4A11XKC36RNQHBB08S64ACRHN", "bibtex": "@misc{statecouncil2026pharmaceutical4acrhn,\n author = {{State Council of China}},\n title = {Value of China's innovative drug out-licensing deals hit new high in H1},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_V4A11XKC36RNQHBB08S64ACRHN},\n note = {Original source: https://english.www.gov.cn/archive/statistics/202607/20/content\\_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_3G7S0FFSCZ2AZP77S1QGNWQFFZ", "url": "https://statorigin.org/stat/stat_3G7S0FFSCZ2AZP77S1QGNWQFFZ", "indicator": { "slug": "pharmaceutical-industry-export-delivery-value-half-year", "name": "Pharmaceutical industry export delivery value (half year)", "definition": "Total value of pharmaceutical industry products delivered for export." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 210, "value_text": "210 billion yuan", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Value of China's innovative drug out-licensing deals hit new high in H1", "document_url": "https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html", "document_type": "press_release", "locator": "Value of China's innovative drug out-licensing deals hit new high in H1", "quote": "The industry's export delivery value exceeded 210 billion yuan (about 30.91 billion U.S. dollars) in the first six months, up 9 percent from a year earlier.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). Value of China's innovative drug out-licensing deals hit new high in H1. Retrieved September 17, 2026, from https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Via StatOrigin, https://statorigin.org/stat/stat_3G7S0FFSCZ2AZP77S1QGNWQFFZ", "bibtex": "@misc{statecouncil2026pharmaceuticalnwqffz,\n author = {{State Council of China}},\n title = {Value of China's innovative drug out-licensing deals hit new high in H1},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_3G7S0FFSCZ2AZP77S1QGNWQFFZ},\n note = {Original source: https://english.www.gov.cn/archive/statistics/202607/20/content\\_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_EVF2RBA5V3YFSQBWJTCC7AVM9Y", "url": "https://statorigin.org/stat/stat_EVF2RBA5V3YFSQBWJTCC7AVM9Y", "indicator": { "slug": "pharmaceutical-industry-export-delivery-value-half-year", "name": "Pharmaceutical industry export delivery value (half year)", "definition": "Total value of pharmaceutical industry products delivered for export." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 30.91, "value_text": "30.91 billion U.S. dollars", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Value of China's innovative drug out-licensing deals hit new high in H1", "document_url": "https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html", "document_type": "press_release", "locator": "Value of China's innovative drug out-licensing deals hit new high in H1", "quote": "The industry's export delivery value exceeded 210 billion yuan (about 30.91 billion U.S. dollars) in the first six months, up 9 percent from a year earlier.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). Value of China's innovative drug out-licensing deals hit new high in H1. Retrieved September 17, 2026, from https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Via StatOrigin, https://statorigin.org/stat/stat_EVF2RBA5V3YFSQBWJTCC7AVM9Y", "bibtex": "@misc{statecouncil2026pharmaceutical7avm9y,\n author = {{State Council of China}},\n title = {Value of China's innovative drug out-licensing deals hit new high in H1},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_EVF2RBA5V3YFSQBWJTCC7AVM9Y},\n note = {Original source: https://english.www.gov.cn/archive/statistics/202607/20/content\\_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_YABFYJCS9AQZNP55ZF5P6GHRNW", "url": "https://statorigin.org/stat/stat_YABFYJCS9AQZNP55ZF5P6GHRNW", "indicator": { "slug": "pharmaceutical-value-added-industrial-output-growth-half-year", "name": "Pharmaceutical value-added industrial output growth (half year)", "definition": "Year-on-year growth rate of value-added industrial output of major pharmaceutical manufacturing enterprises." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 6.4, "value_text": "6.4 percent", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Value of China's innovative drug out-licensing deals hit new high in H1", "document_url": "https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html", "document_type": "press_release", "locator": "Value of China's innovative drug out-licensing deals hit new high in H1", "quote": "From January to June, value-added industrial output of major pharmaceutical enterprises rose 6.4 percent year on year, with biopharmaceuticals posting double-digit growth.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2026). Value of China's innovative drug out-licensing deals hit new high in H1. Retrieved September 17, 2026, from https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Via StatOrigin, https://statorigin.org/stat/stat_YABFYJCS9AQZNP55ZF5P6GHRNW", "bibtex": "@misc{statecouncil2026pharmaceutical6ghrnw,\n author = {{State Council of China}},\n title = {Value of China's innovative drug out-licensing deals hit new high in H1},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_YABFYJCS9AQZNP55ZF5P6GHRNW},\n note = {Original source: https://english.www.gov.cn/archive/statistics/202607/20/content\\_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_F7KHZB38RZH371VBY13Z6TF2PA", "url": "https://statorigin.org/stat/stat_F7KHZB38RZH371VBY13Z6TF2PA", "indicator": { "slug": "priority-review-drug-approval-applications-completed-growth-rate", "name": "Priority review drug approval applications completed growth rate", "definition": "Year-on-year percentage change in completed priority review drug approval applications." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 29, "value_text": "29 percent", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "\"In 2024, the administration completed 110 drug approval applications covering 74 different categories under the priority review pathway, marking a year-on-year increase of 29 percent,\" Yuan said.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_F7KHZB38RZH371VBY13Z6TF2PA", "bibtex": "@misc{statecouncil2024priority6tf2pa,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_F7KHZB38RZH371VBY13Z6TF2PA},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_7WZNMPQS2F117VY0H13JHVN57S", "url": "https://statorigin.org/stat/stat_7WZNMPQS2F117VY0H13JHVN57S", "indicator": { "slug": "projected-patient-out-of-pocket-burden-reduction", "name": "Projected patient out-of-pocket burden reduction", "definition": "Forecasted reduction in patient medical expenses resulting from negotiated price cuts and reimbursement coverage." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 50, "value_text": "超500亿元", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "forecast", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药", "quote": "叠加谈判降价和医保报销因素，预计2025年将为患者减负超500亿元。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2025). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_7WZNMPQS2F117VY0H13JHVN57S", "bibtex": "@misc{statecouncil2025projectedhvn57s,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7WZNMPQS2F117VY0H13JHVN57S},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_NAEE4RMBKCEWWVM3ZC0P1MS13R", "url": "https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R", "indicator": { "slug": "rare-disease-drug-varieties-approved", "name": "Rare disease drug varieties approved", "definition": "Total number of drug varieties approved for the treatment of rare diseases." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 39, "value_text": "39个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202501/content_6997982.htm", "document_type": "press_release", "locator": "更好满足临床急需", "quote": "不只注射用利纳西普，据罕见病信息网统计，全年批准罕见病用药39个品种，覆盖了34种罕见病。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202501/content_6997982.htm. Via StatOrigin, https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R", "bibtex": "@misc{statecouncil2024rare1ms13r,\n author = {{State Council of China}},\n title = {全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_NAEE4RMBKCEWWVM3ZC0P1MS13R},\n note = {Original source: https://www.gov.cn/zhengce/202501/content\\_6997982.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_3WP693DTEGSQN8M677VCJTCBX1", "url": "https://statorigin.org/stat/stat_3WP693DTEGSQN8M677VCJTCBX1", "indicator": { "slug": "rare-disease-medicine-approvals", "name": "Rare disease medicine approvals", "definition": "Number of rare disease medicines granted market approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 55, "value_text": "55", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Furthermore, 55 rare disease medicines were authorized for market last year.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_3WP693DTEGSQN8M677VCJTCBX1", "bibtex": "@misc{statecouncil2024rarejtcbx1,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_3WP693DTEGSQN8M677VCJTCBX1},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_5GR698TPGG2W8JVGV7AE181GT1", "url": "https://statorigin.org/stat/stat_5GR698TPGG2W8JVGV7AE181GT1", "indicator": { "slug": "reimbursement-drug-list-total-drugs", "name": "Reimbursement drug list total drugs", "definition": "Total number of pharmaceutical products covered by a national or public reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-11-28", "end": "2024-11-28", "type": "point" }, "value": 3159, "value_text": "3159种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药", "quote": "在今年的调整中，有91种药品新增进入国家医保药品目录，药品总数增至3159种，目录自2025年1月1日起实施。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_5GR698TPGG2W8JVGV7AE181GT1", "bibtex": "@misc{statecouncil2024reimbursement181gt1,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_5GR698TPGG2W8JVGV7AE181GT1},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_YPRB992163ZBAGNZW8795F4MFC", "url": "https://statorigin.org/stat/stat_YPRB992163ZBAGNZW8795F4MFC", "indicator": { "slug": "reimbursement-drug-list-total-drugs", "name": "Reimbursement drug list total drugs", "definition": "Total number of pharmaceutical products covered by a national or public reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-12-07", "end": "2025-12-07", "type": "point" }, "value": 3253, "value_text": "3,253", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China updates national medical insurance catalog, adds 114 new drugs", "document_url": "https://english.www.gov.cn/news/202512/07/content_WS6934f5f6c6d00ca5f9a07f64.html", "document_type": "press_release", "locator": "China updates national medical insurance catalog, adds 114 new drugs", "quote": "The country's medical insurance authority has adjusted the list for eight years in a row, increasing the total number of medications to 3,253 and significantly improving coverage in key areas such as oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2025). China updates national medical insurance catalog, adds 114 new drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202512/07/content_WS6934f5f6c6d00ca5f9a07f64.html. Via StatOrigin, https://statorigin.org/stat/stat_YPRB992163ZBAGNZW8795F4MFC", "bibtex": "@misc{statecouncil2025reimbursement5f4mfc,\n author = {{State Council of China}},\n title = {China updates national medical insurance catalog, adds 114 new drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_YPRB992163ZBAGNZW8795F4MFC},\n note = {Original source: https://english.www.gov.cn/news/202512/07/content\\_WS6934f5f6c6d00ca5f9a07f64.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_GXTAFX17EAE3M3M2YPSRA2GZVV", "url": "https://statorigin.org/stat/stat_GXTAFX17EAE3M3M2YPSRA2GZVV", "indicator": { "slug": "share-of-global-biopharmaceutical-licensing-deals", "name": "Share of global biopharmaceutical licensing deals", "definition": "Proportion of global biopharmaceutical licensing agreements involving entities from a specific country or region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 20, "value_text": "about one-fifth", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China to expand health insurance coverage for innovative drugs", "document_url": "https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html", "document_type": "press_release", "locator": "China to expand health insurance coverage for innovative drugs", "quote": "By 2025, China accounted for about 30 percent of the global biopharma pipeline, up from just 2 percent a decade earlier, and about one-fifth of global licensing deals, according to McKinsey research.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2025). China to expand health insurance coverage for innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html. Via StatOrigin, https://statorigin.org/stat/stat_GXTAFX17EAE3M3M2YPSRA2GZVV", "bibtex": "@misc{statecouncil2025sharea2gzvv,\n author = {{State Council of China}},\n title = {China to expand health insurance coverage for innovative drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_GXTAFX17EAE3M3M2YPSRA2GZVV},\n note = {Original source: https://english.www.gov.cn/news/202609/04/content\\_WS6a9a7481c6d00ca5f9a0d02f.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_Y9M9YA7PN9SAGRCQS4CT007F83", "url": "https://statorigin.org/stat/stat_Y9M9YA7PN9SAGRCQS4CT007F83", "indicator": { "slug": "share-of-global-biopharmaceutical-pipeline", "name": "Share of global biopharmaceutical pipeline", "definition": "Proportion of global biopharmaceutical research and development pipeline assets originating from a specific country or region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 30, "value_text": "about 30 percent", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China to expand health insurance coverage for innovative drugs", "document_url": "https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html", "document_type": "press_release", "locator": "China to expand health insurance coverage for innovative drugs", "quote": "By 2025, China accounted for about 30 percent of the global biopharma pipeline, up from just 2 percent a decade earlier, and about one-fifth of global licensing deals, according to McKinsey research.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2025). China to expand health insurance coverage for innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html. Via StatOrigin, https://statorigin.org/stat/stat_Y9M9YA7PN9SAGRCQS4CT007F83", "bibtex": "@misc{statecouncil2025share007f83,\n author = {{State Council of China}},\n title = {China to expand health insurance coverage for innovative drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Y9M9YA7PN9SAGRCQS4CT007F83},\n note = {Original source: https://english.www.gov.cn/news/202609/04/content\\_WS6a9a7481c6d00ca5f9a0d02f.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_JYR9Z0QMER0P06T03ABQPATAYZ", "url": "https://statorigin.org/stat/stat_JYR9Z0QMER0P06T03ABQPATAYZ", "indicator": { "slug": "share-of-global-biopharmaceutical-pipeline", "name": "Share of global biopharmaceutical pipeline", "definition": "Proportion of global biopharmaceutical research and development pipeline assets originating from a specific country or region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2015-01-01", "end": "2015-12-31", "type": "year" }, "value": 2, "value_text": "2 percent", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China to expand health insurance coverage for innovative drugs", "document_url": "https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html", "document_type": "press_release", "locator": "China to expand health insurance coverage for innovative drugs", "quote": "By 2025, China accounted for about 30 percent of the global biopharma pipeline, up from just 2 percent a decade earlier, and about one-fifth of global licensing deals, according to McKinsey research.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2015). China to expand health insurance coverage for innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202609/04/content_WS6a9a7481c6d00ca5f9a0d02f.html. Via StatOrigin, https://statorigin.org/stat/stat_JYR9Z0QMER0P06T03ABQPATAYZ", "bibtex": "@misc{statecouncil2015sharepatayz,\n author = {{State Council of China}},\n title = {China to expand health insurance coverage for innovative drugs},\n year = {2015},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JYR9Z0QMER0P06T03ABQPATAYZ},\n note = {Original source: https://english.www.gov.cn/news/202609/04/content\\_WS6a9a7481c6d00ca5f9a0d02f.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_BZK23J65GQN97SGQPZBKQW5SWT", "url": "https://statorigin.org/stat/stat_BZK23J65GQN97SGQPZBKQW5SWT", "indicator": { "slug": "share-of-priority-review-drug-approval-applications-treating-cancer", "name": "Share of priority review drug approval applications treating cancer", "definition": "Percentage share of priority review drug approval applications targeting oncology indications." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "point" }, "value": 42.54, "value_text": "42.54 percent", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_BZK23J65GQN97SGQPZBKQW5SWT", "bibtex": "@misc{statecouncil2024shareqw5swt,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_BZK23J65GQN97SGQPZBKQW5SWT},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" } ] }, "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 44, "note": "Statistics are capped at 100 per request. Use /statistics?source_org=state-council-of-china with a cursor to page through everything." } }